Patient-, disease-, and transplantation-related characteristics
. | Type of transplant . | . | . | ||
|---|---|---|---|---|---|
| Variables . | HLA-identical sibling . | Autologous purged . | Autologous unpurged . | ||
| N | 176 | 131 | 597 | ||
| Median age, y (range) | 42 (22-64) | 49 (29-64) | 49 (18-71) | ||
| Men (%) | 95 (54) | 83 (63) | 320 (54) | ||
| Karnofsky performance score at transplantation (%)* | |||||
| No more than 80% | 60 (34) | 17 (13) | 183 (31) | ||
| 90%-100% | 116 (66) | 114 (87) | 414 (69) | ||
| CMV status at transplantation (%)* | |||||
| Negative | 85 (48) | 16 (12) | 153 (26) | ||
| Positive | 88 (50) | 32 (25) | 205 (34) | ||
| Unknown | 3 (2) | 83 (63) | 239 (40) | ||
| Disease status at transplantation (%)*† | |||||
| Early | 85 (48) | 69 (53) | 350 (59) | ||
| Advanced | 91 (52) | 62 (47) | 247 (41) | ||
| Bone marrow involvement at diagnosis (%) | |||||
| Absent | 102 (58) | 71 (54) | 355 (59) | ||
| Present | 74 (42) | 60 (46) | 242 (41) | ||
| Bone marrow involvement at transplantation (%)* | |||||
| Absent | 119 (68) | 103 (79) | 486 (81) | ||
| Present | 57 (32) | 28 (21) | 111 (19) | ||
| Histology (%)* | |||||
| Follicular, small cleaved | 91 (52) | 67 (51) | 218 (36) | ||
| Follicular, mixed small and large | 72 (41) | 52 (40) | 242 (41) | ||
| Follicular, large cell | 13 (7) | 12 (9) | 137 (23) | ||
| Disease stage at diagnosis (%) | |||||
| I-II | 22 (13) | 23 (17) | 113 (19) | ||
| III-IV | 152 (86) | 107 (82) | 476 (80) | ||
| Unknown | 2 (1) | 1 (1) | 8 (1) | ||
| B symptoms at diagnosis (%) | |||||
| Absent | 116 (66) | 94 (72) | 367 (62) | ||
| Present | 48 (27) | 33 (25) | 182 (30) | ||
| Unknown | 12 (7) | 4 (3) | 48 (8) | ||
| Chemosensitivity (%)* | |||||
| Sensitive | 118 (67) | 111 (85) | 488 (82) | ||
| Resistant | 31 (18) | 14 (11) | 66 (11) | ||
| Untreated/unknown | 27 (15) | 6 (4) | 43 (7) | ||
| Serum LDH at diagnosis (%)* | |||||
| Normal | 117 (67) | 55 (42) | 389 (65) | ||
| Abnormal | 44 (25) | 27 (21) | 174 (29) | ||
| Unknown | 15 (8) | 49 (37) | 34 (6) | ||
| Initial chemotherapy (%)* | |||||
| CHOP ± other | 44 (25) | 57 (44) | 206 (34) | ||
| Fludarabine ± other | 29 (16) | 7 (5) | 63 (11) | ||
| Other | 44 (25) | 32 (24) | 221 (37) | ||
| Unknown | 59 (34) | 35 (27) | 107 (18) | ||
| Interval from diagnosis to transplantation (%) | |||||
| Less than 1 y | 26 (15) | 27 (21) | 115 (19) | ||
| 1-2 y | 56 (32) | 32 (24) | 156 (26) | ||
| More than 2 y | 94 (53) | 72 (55) | 326 (55) | ||
| Graft type (%)* | |||||
| Bone marrow | 135 (77) | 100 (76) | 89 (15) | ||
| Peripheral blood/both | 41 (23) | 31 (24) | 508 (85) | ||
| Year of transplantation (%)* | |||||
| 1990-1993 | 50 (28) | 70 (54) | 181 (30) | ||
| 1994-1996 | 64 (37) | 41 (31) | 269 (45) | ||
| 1997-1999 | 62 (35) | 20 (15) | 147 (25) | ||
| Conditioning regimen (%)* | |||||
| TBI | 120 (68) | 44 (34) | 184 (31) | ||
| Non-TBI | 56 (32) | 87 (66) | 413 (69) | ||
| Use of involved field radiation (%) | |||||
| No | 169 (96) | 128 (98) | 576 (96) | ||
| Yes | 7 (4) | 3 (2) | 21 (4) | ||
| GVHD prophylaxis (%) | |||||
| T-cell depletion | 28 (16) | — | — | ||
| MTX ± other | 113 (64) | — | — | ||
| CSA ± other/other or none | 35 (20) | — | — | ||
| AGVHD (%) | |||||
| None-mild | 108 (61) | — | — | ||
| Moderate-severe | 65 (37) | — | — | ||
| Unknown | 3 (2) | — | — | ||
| Chronic GVHD (%) | |||||
| None | 131 (74) | — | — | ||
| Mild-severe | 42 (24) | — | — | ||
| Unknown | 3 (2) | — | — | ||
| Number of centers | 56 | 21 | 98 | ||
. | Type of transplant . | . | . | ||
|---|---|---|---|---|---|
| Variables . | HLA-identical sibling . | Autologous purged . | Autologous unpurged . | ||
| N | 176 | 131 | 597 | ||
| Median age, y (range) | 42 (22-64) | 49 (29-64) | 49 (18-71) | ||
| Men (%) | 95 (54) | 83 (63) | 320 (54) | ||
| Karnofsky performance score at transplantation (%)* | |||||
| No more than 80% | 60 (34) | 17 (13) | 183 (31) | ||
| 90%-100% | 116 (66) | 114 (87) | 414 (69) | ||
| CMV status at transplantation (%)* | |||||
| Negative | 85 (48) | 16 (12) | 153 (26) | ||
| Positive | 88 (50) | 32 (25) | 205 (34) | ||
| Unknown | 3 (2) | 83 (63) | 239 (40) | ||
| Disease status at transplantation (%)*† | |||||
| Early | 85 (48) | 69 (53) | 350 (59) | ||
| Advanced | 91 (52) | 62 (47) | 247 (41) | ||
| Bone marrow involvement at diagnosis (%) | |||||
| Absent | 102 (58) | 71 (54) | 355 (59) | ||
| Present | 74 (42) | 60 (46) | 242 (41) | ||
| Bone marrow involvement at transplantation (%)* | |||||
| Absent | 119 (68) | 103 (79) | 486 (81) | ||
| Present | 57 (32) | 28 (21) | 111 (19) | ||
| Histology (%)* | |||||
| Follicular, small cleaved | 91 (52) | 67 (51) | 218 (36) | ||
| Follicular, mixed small and large | 72 (41) | 52 (40) | 242 (41) | ||
| Follicular, large cell | 13 (7) | 12 (9) | 137 (23) | ||
| Disease stage at diagnosis (%) | |||||
| I-II | 22 (13) | 23 (17) | 113 (19) | ||
| III-IV | 152 (86) | 107 (82) | 476 (80) | ||
| Unknown | 2 (1) | 1 (1) | 8 (1) | ||
| B symptoms at diagnosis (%) | |||||
| Absent | 116 (66) | 94 (72) | 367 (62) | ||
| Present | 48 (27) | 33 (25) | 182 (30) | ||
| Unknown | 12 (7) | 4 (3) | 48 (8) | ||
| Chemosensitivity (%)* | |||||
| Sensitive | 118 (67) | 111 (85) | 488 (82) | ||
| Resistant | 31 (18) | 14 (11) | 66 (11) | ||
| Untreated/unknown | 27 (15) | 6 (4) | 43 (7) | ||
| Serum LDH at diagnosis (%)* | |||||
| Normal | 117 (67) | 55 (42) | 389 (65) | ||
| Abnormal | 44 (25) | 27 (21) | 174 (29) | ||
| Unknown | 15 (8) | 49 (37) | 34 (6) | ||
| Initial chemotherapy (%)* | |||||
| CHOP ± other | 44 (25) | 57 (44) | 206 (34) | ||
| Fludarabine ± other | 29 (16) | 7 (5) | 63 (11) | ||
| Other | 44 (25) | 32 (24) | 221 (37) | ||
| Unknown | 59 (34) | 35 (27) | 107 (18) | ||
| Interval from diagnosis to transplantation (%) | |||||
| Less than 1 y | 26 (15) | 27 (21) | 115 (19) | ||
| 1-2 y | 56 (32) | 32 (24) | 156 (26) | ||
| More than 2 y | 94 (53) | 72 (55) | 326 (55) | ||
| Graft type (%)* | |||||
| Bone marrow | 135 (77) | 100 (76) | 89 (15) | ||
| Peripheral blood/both | 41 (23) | 31 (24) | 508 (85) | ||
| Year of transplantation (%)* | |||||
| 1990-1993 | 50 (28) | 70 (54) | 181 (30) | ||
| 1994-1996 | 64 (37) | 41 (31) | 269 (45) | ||
| 1997-1999 | 62 (35) | 20 (15) | 147 (25) | ||
| Conditioning regimen (%)* | |||||
| TBI | 120 (68) | 44 (34) | 184 (31) | ||
| Non-TBI | 56 (32) | 87 (66) | 413 (69) | ||
| Use of involved field radiation (%) | |||||
| No | 169 (96) | 128 (98) | 576 (96) | ||
| Yes | 7 (4) | 3 (2) | 21 (4) | ||
| GVHD prophylaxis (%) | |||||
| T-cell depletion | 28 (16) | — | — | ||
| MTX ± other | 113 (64) | — | — | ||
| CSA ± other/other or none | 35 (20) | — | — | ||
| AGVHD (%) | |||||
| None-mild | 108 (61) | — | — | ||
| Moderate-severe | 65 (37) | — | — | ||
| Unknown | 3 (2) | — | — | ||
| Chronic GVHD (%) | |||||
| None | 131 (74) | — | — | ||
| Mild-severe | 42 (24) | — | — | ||
| Unknown | 3 (2) | — | — | ||
| Number of centers | 56 | 21 | 98 | ||
CMV indicates cytomegalovirus; CHOP, cyclophosphamide, hydroxydaunomycin, Oncovin, prednisone; MTX, methotrexate; CSA, cyclosporin A; —, not applicable; and AGVHD, acute graft-versus-host disease.
P <.01 for difference between transplant groups.
Early disease indicates patients whose disease status at transplantation is in first or second complete remission, or in first relapse; advanced disease, patients whose disease status at transplantation is in second or greater relapse, in third complete remission, or with primary induction failure.